Upfront riociguat and ambrisentan combination therapy for newly diagnosed pulmonary arterial hypertension: A prospective open-label trial.

导出 LinkOut

翻译打印收藏纠错

作者： Jason,Weatherald ^[1] ; Mitesh V,Thakrar ^[2] ; Rhea A,Varughese ^[3] ; Mithum,Kularatne ^[2] ; Jonathan,Liu ^[2] ; Lea,Harper ^[2] ; Omid,Kiamanesh ^[4] ; Nowell,Fine ^[4] ; Evan,Orlikow ^[5] ; Chidera,Nwaroh ^[6] ; Christina,Thornton ^[2] ; John,Swiston ^[7] ; Lisa,Kolkman ^[7] ; Nathan W,Brunner ^[8] ; Doug,Helmersen ^[2] ; Naushad,Hirani ^[2]

作者单位： Department of Medicine, Division of Respirology, University of Calgary, Calgary, Canada; Libin Cardiovascular Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, Canada. Electronic address: jason.weatherald@ahs.ca. ^[1] Department of Medicine, Division of Respirology, University of Calgary, Calgary, Canada. ^[2] Department of Medicine, Division of Respirology, University of Calgary, Calgary, Canada; Department of Medicine, Division of Pulmonary Medicine, University of Alberta, Edmonton, Canada. ^[3] Libin Cardiovascular Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, Canada; Department of Cardiac Sciences, Division of Cardiology, University of Calgary, Calgary, Canada. ^[4] Department of Medicine, University of Manitoba, Winnipeg, Canada. ^[5] Cumming School of Medicine, University of Calgary, Calgary, Canada. ^[6] Department of Medicine, Division of Respiratory Medicine, University of British Columbia, Vancouver, Canada. ^[7] Department of Medicine, Division of Cardiology, University of British Columbia, Vancouver, Canada. ^[8]

关键词 ambrisentan combination therapy pulmonary arterial hypertension riociguat